公开(公告)号：US11690830B2

公开(公告)日：2023-07-04

申请号：US17396064

申请日：2021-08-06

申请人： INTRABIO LTD.

发明人： Michael Strupp

IPC分类号： A61K31/4402 ,  A61P25/00 ,  A61K9/00 ,  A61K31/137

CPC分类号： A61K31/4402 ,  A61K9/0053 ,  A61K31/137 ,  A61P25/00

摘要： A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject.
A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

公开(公告)号：US11471434B2

公开(公告)日：2022-10-18

申请号：US16622785

申请日：2018-06-25

申请人： INTRABIO LTD.

发明人： Michael Strupp ,  Mallory Factor

IPC分类号： A61K31/198

摘要： A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11083718B2

公开(公告)日：2021-08-10

申请号：US16499087

申请日：2018-03-28

申请人： INTRABIO LTD

发明人： Michael Strupp

IPC分类号： A61K31/4402 ,  A61P25/00 ,  A61K9/00 ,  A61K31/137

摘要： A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

公开(公告)号：US12121513B2

公开(公告)日：2024-10-22

申请号：US18320761

申请日：2023-05-19

申请人： IntraBio Ltd.

发明人： Michael Strupp

IPC分类号： A61K31/4402 ,  A61K9/00 ,  A61K31/137 ,  A61P25/00

CPC分类号： A61K31/4402 ,  A61K9/0053 ,  A61K31/137 ,  A61P25/00

摘要： A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject.
A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

公开(公告)号：US11998518B2

公开(公告)日：2024-06-04

申请号：US17247757

申请日：2020-12-22

申请人： INTRABIO LTD.

发明人： Mallory Factor ,  Michael Strupp

IPC分类号： A61K31/198 ,  A61P25/28

CPC分类号： A61K31/198 ,  A61P25/28

摘要： The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.

公开(公告)号：US11660279B2

公开(公告)日：2023-05-30

申请号：US16968919

申请日：2019-02-14

申请人： INTRABIO LTD

发明人： Mallory Factor ,  Michael Strupp

IPC分类号： A61K31/198 ,  A61P25/00

CPC分类号： A61K31/198 ,  A61P25/00

摘要： The present disclosure provides for treatments of restless legs syndrome (RLS) or one or more symptoms associated with RLS comprising administering leucine, acetyl-leucine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210361632A1

公开(公告)日：2021-11-25

申请号：US17396064

申请日：2021-08-06

申请人： IntraBio Ltd.

发明人： Michael Strupp

IPC分类号： A61K31/4402 ,  A61P25/00 ,  A61K9/00 ,  A61K31/137

摘要： A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject.
A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.

公开(公告)号：US10905670B2

公开(公告)日：2021-02-02

申请号：US16093780

申请日：2017-04-19

申请人： IntraBio Ltd.

发明人： Mallory Factor ,  Michael Strupp

IPC分类号： A61K31/198 ,  A61P25/28

摘要： The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.

公开(公告)号：US20190083438A1

公开(公告)日：2019-03-21

申请号：US16093780

申请日：2017-04-19

申请人： IntraBio Ltd.

发明人： Mallory Factor ,  Michael Strupp

IPC分类号： A61K31/198 ,  A61P25/28

摘要： The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.